Detalhe da pesquisa
1.
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Br J Haematol
; 180(2): 224-235, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29193019
2.
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
N Engl J Med
; 372(10): 944-53, 2015 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25738670
3.
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Lancet Oncol
; 17(3): 319-331, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899778
4.
Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.
Front Oncol
; 13: 1138683, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37007128
5.
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Blood
; 114(6): 1166-73, 2009 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-19470696
6.
Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure.
Biology (Basel)
; 9(2)2020 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32050707
7.
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
J Clin Oncol
; 27(36): 6086-93, 2009 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19858394